|
⚲
|
| Keyboard |
| Keros Therapeutics Inc
✚
|
|
|---|---|
| CIK # | 0001664710 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 10-K | [0001664710] | |
| 10-Q | [0001664710] | |
| 3 | [0001664710] | |
| 4 | [0001664710] | |
| 8-K | [0001664710] | |
| D | [0001664710] | |
| SC 13D | [0001664710] | |
| SC 13G | [0001664710] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Prener Anne | |
| Keros Therapeutics Inc | |
| Bienaime Jean Jacques | |
| Newton Charles W | |
| Knowles Julius | |
| Farzan Nima | |
| Gray Mary Ann | |
| Seth Alpna | |
| Seehra Jasbir | |
| Lerner Lorena Raquel | |
| View All | |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Keros Therapeutics Inc KROS
Common Stock
|
2026-03-09 | Grant | 13,215 | $0.00 | |
|
Keros Therapeutics Inc KROS
Stock Option (Right to Buy) · derivative
|
2026-03-09 | Grant | 14,788 | $0.00 | |
|
Keros Therapeutics Inc KROS
Common Stock
|
2026-03-09 | Buy | 2,000 | $11.21 | 22,420 |
|
Keros Therapeutics Inc KROS
Employee Stock Option (Right to Buy) · derivative
|
2026-02-24 | Grant | 80,000 | $0.00 | |
|
Keros Therapeutics Inc KROS
Employee Stock Option (right to buy) · derivative
|
2026-02-24 | Grant | 100,000 | $0.00 | |
|
Keros Therapeutics Inc KROS
Employee Stock Option (Right to Buy) · derivative
|
2026-02-24 | Grant | 60,000 | $0.00 | |
|
Keros Therapeutics Inc KROS
Employee Stock Option (Right to Buy) · derivative
|
2026-02-24 | Grant | 75,000 | $0.00 | |
|
Keros Therapeutics Inc KROS
Employee Stock Option (Right to Buy) · derivative
|
2026-02-24 | Grant | 217,000 | $0.00 | |
|
Keros Therapeutics Inc KROS
Common Stock
|
2026-02-19 | Sell | 7,015 | $16.17 | 113,433 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2026-02-18 | Sell | 4,739 | $16.35 | 77,483 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2026-02-18 | Sell | 4,745 | $16.35 | 77,581 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2026-02-18 | Sell | 3,873 | $16.35 | 63,324 |
|
Keros Therapeutics Inc KROS
Employee Stock Option (right to buy) · derivative
|
2026-01-07 | Grant | 62,500 | $0.00 | |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-11-21 | Disposed to issuer | 130,494 | $17.75 | 2,316,268 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-11-21 | Disposed to issuer | 191,527 | $17.75 | 3,399,604 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-11-21 | Disposed to issuer | 140,057 | $17.75 | 2,486,012 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-11-21 | Disposed to issuer | 74,465 | $17.75 | 1,321,754 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-11-21 | Disposed to issuer | 140,057 | $17.75 | 2,486,012 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-11-21 | Disposed to issuer | 74,465 | $17.75 | 1,321,754 |
|
Keros Therapeutics Inc KROS
Common Stock, $0.0001 par value per share
|
2025-10-15 | Sell | 2,284,612 | $17.75 | 40,551,863 |
| showing 20 of 200 most recent transactions | |||||